The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands

Anne M. Spanjaart, on behalf of the Dutch CAR-T Tumorboard Consortium, Elise R.A. Pennings, Pim G.N.J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke W. de Boer, Anne G.H. Niezink, Milan Kos, Joost S.P. Vermaat, Aniko Sijs-Szabo, Marjolein W.M. van der Poel, Inger S. Nijhof, Maria T. Kuipers, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Jeanette K. Doorduijn, Yasmina I.M. Serroukh, Monique C. MinnemaTom van Meerten, Marie José Kersten*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
39 Downloads (Pure)

Abstract

The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, the CAR-T tumorboard facilitates a unique nationwide infrastructure for referral, eligibility assessment and data collection. The aim of this study was to evaluate real-world outcomes of axicabtagene ciloleucel (axi-cel) in the Dutch population, including the thus-far underreported effects on health-related quality of life (HR-QoL). All patients with R/R LBCL after ≥2 lines of systemic therapy referred for axi-cel treatment between May 2020–May 2022 were included (N = 250). Of the 160 apheresed patients, 145 patients received an axi-cel infusion. The main reason for ineligibility was rapidly progressive disease. The outcomes are better or at least comparable to other studies (best overall response rate: 84% (complete response: 66%); 12-month progression-free-survival rate and overall survival rate: 48% and 62%, respectively). The 12-month NRM was 5%, mainly caused by infections. Clinically meaningful improvement in several HR-QoL domains was observed from Month 9 onwards. Expert-directed patient selection can support effective and sustainable application of CAR-T treatment. Matched comparisons between cohorts will help to understand the differences in outcomes across countries and select best practices. Despite the favorable results, for a considerable proportion of patients with R/R LBCL there still is an unmet medical need.

Original languageEnglish
Article number4334
JournalCancers
Volume15
Issue number17
DOIs
Publication statusPublished - Sept 2023

Bibliographical note

Funding Information:
A.M.S. is funded by the European Union’s Horizon 2020 Research and Innovation Program under the grant agreement number 875171, QUALITOP. E.R.A.P. is funded by the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 116026), T2EVOLVE. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Publisher Copyright: © 2023 by the authors.

Fingerprint

Dive into the research topics of 'The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands'. Together they form a unique fingerprint.

Cite this